⌕
Iovance Biotherapeutics · IOVA · Nasdaq
Tenet 52 · Mixed
Compare
$7.55−2.71%At closeTenet 52 · Mixed
$7.55−0.21 (−2.71%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Iovance Biotherapeutics (IOVA) Institutional Ownership

13F filers reported holding 63.8% of Iovance Biotherapeutics (IOVA) shares as of Jun 30, 2026, across 294 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

4 figures withheld by our checks. Each blank figure names its reason.

Held by 13F filers
63.8%
Jun 30, 2026
13F filers
294
quarter ended Jun 30, 2026
13F value
$1.2B
295.2M shares

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 294 13F filers for Jun 30, 2026, over shares outstanding implied from the current quote, measured 140 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 30, 2026Berkowitz NoahChief Medical OfficerAcquired · Grant / award135,000Stock Options (Right to Buy)—↗
Sep 30, 2026Berkowitz NoahChief Medical OfficerAcquired · Grant / award180,000Restricted Stock Units—↗
Sep 30, 2026Berkowitz NoahChief Medical OfficerAcquired · Grant / award135,000Performance Stock Units—↗
Sep 8, 2026Vogt Frederick GInterim CEO & General CounselAcquired · Option exercise15,626—↗
Sep 8, 2026Vogt Frederick GInterim CEO & General CounselDisposed · Tax withholding6,638$8.70↗
Sep 8, 2026Vogt Frederick GInterim CEO & General CounselDisposed · Option exercise15,626Restricted Stock Units—↗
Sep 8, 2026BILINSKY IGORChief Operating OfficerAcquired · Option exercise7,813—↗
Sep 8, 2026BILINSKY IGORChief Operating OfficerDisposed · Tax withholding3,976$8.70↗
Sep 8, 2026BILINSKY IGORChief Operating OfficerDisposed · Option exercise7,813Restricted Stock Units—↗
Sep 8, 2026Puri Raj K.Chief Regulatory OfficerAcquired · Option exercise9,766—↗
Sep 8, 2026Puri Raj K.Chief Regulatory OfficerDisposed · Tax withholding4,478$8.70↗
Sep 8, 2026Puri Raj K.Chief Regulatory OfficerDisposed · Option exercise9,766Restricted Stock Units—↗
Sep 1, 2026Vogt Frederick GInterim CEO & General CounselAcquired · Option exercise41,669—↗
Sep 1, 2026Vogt Frederick GInterim CEO & General CounselDisposed · Tax withholding17,702$8.28↗
Sep 1, 2026Vogt Frederick GInterim CEO & General CounselDisposed · Option exercise41,669Restricted Stock Units—↗
Sep 1, 2026Puri Raj K.Chief Regulatory OfficerAcquired · Option exercise5,470—↗
Sep 1, 2026Puri Raj K.Chief Regulatory OfficerDisposed · Tax withholding2,508$8.28↗
Sep 1, 2026Puri Raj K.Chief Regulatory OfficerDisposed · Option exercise5,470Restricted Stock Units—↗
Sep 1, 2026BILINSKY IGORChief Operating OfficerAcquired · Option exercise8,789—↗
Sep 1, 2026BILINSKY IGORChief Operating OfficerDisposed · Tax withholding4,472$8.28↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Iovance Biotherapeutics do institutions hold?

13F filers reported holding 63.8% of Iovance Biotherapeutics' shares as of Jun 30, 2026, across 294 filers.

How many 13F filers hold Iovance Biotherapeutics?

Iovance Biotherapeutics was held by 294 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.